HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lockwood, C. J. Search for Related Content PubMed PubMed Citation Articles by Lockwood, C. J.

Inherited Thrombophilias in Pregnant Patients: Detection and Treatment Paradigm

From the Department of Obstetrics and Gynecology, New York University School of Medicine, New York, New York.

Address reprint requests to: Charles J. Lockwood, MD, The Stanley H. Kaplan, Professor and Chair, Department of Obstetrics and Gynecology, New York University School of Medicine, 550 First Avenue, New York, NY 10016; E-mail: Charles. Lockwood{at}med.nyu.edu.

Inherited thrombophilias are the leading cause of maternal thromboembolism and are associated with an increased risk of certain adverse pregnancy outcomes including second- and third-trimester fetal loss, abruptions, severe intrauterine growth restriction, and early-onset, severe preeclampsia. Current information suggests that all patients with a history of prior venous thrombotic events and those with these characteristic adverse pregnancy events should be evaluated for thrombophilias. The most common, clinically significant, inherited thrombophilias are heterozygosity for the factor V Leiden and prothrombin G20210A mutations. The autosomal-dominant deficiencies of protein C and protein S are of comparable thrombogenic potential but are far less common. Homozygosity for the 4G/4G mutation in the type-1 plasminogen activator inhibitor gene and the thermolabile variant of the methylenetetrahydrofolate reductase gene, the leading cause of hyperhomocysteinemia, although relatively common, confer a low risk of thrombosis. In contrast, autosomal-dominant antithrombin deficiency and homozygosity or compound heterozygosity (ie, carriers of one copy of each mutant allele) for the factor V and prothrombin mutations are very rare but highly thrombogenic states. Regardless of their antecedent histories, pregnant patients with these highly thrombogenic conditions are at very high risk for both thromboembolism and characteristic adverse pregnancy outcomes, require full therapeutic heparin therapy throughout pregnancy, and need at least 6 weeks of postpartum oral anticoagulation. There is also compelling evidence that patients with the less thrombogenic thrombophilias and a history of venous thrombotic events or characteristic adverse pregnancy outcomes require prophylactic anticoagulant therapy during pregnancy and, in the case of prior thromboembolism, during the puerperium. Antepartum anticoagulation does not appear warranted among patients with less thrombogenic thrombophilias who are without a history of venous thromboembolism, characteristic adverse pregnancy outcomes, or other high risk factors for venous thrombosis.

This article has been cited by other articles:

				G. E. Luzardo, R. A. Karlnoski, B. Williams, D. Mangar, and E. M. Camporesi Anesthetic Management of a Parturient with Hyperhomocysteinemia Anesth. Analg., June 1, 2008; 106(6): 1833 - 1836. [Abstract] [Full Text] [PDF]

				J. Cleary-Goldman, B. Bettes, J. N. Robinson, E. Norwitz, and J. Schulkin Thrombophilia and the Obstetric Patient Obstet. Gynecol., September 1, 2007; 110(3): 669 - 674. [Abstract] [Full Text] [PDF]

				C. V. Ananth, D. Getahun, M. R. Peltier, and J. C. Smulian Placental Abruption in Term and Preterm Gestations: Evidence for Heterogeneity in Clinical Pathways. Obstet. Gynecol., April 1, 2006; 107(4): 785 - 792. [Abstract] [Full Text] [PDF]

				J. Lin and P. August Genetic Thrombophilias and Preeclampsia: A Meta-Analysis Obstet. Gynecol., January 1, 2005; 105(1): 182 - 192. [Abstract] [Full Text] [PDF]

				G. Krikun, D. Sakkas, F. Schatz, L. Buchwalder, D. Hylton, C. Tang, and C. J. Lockwood Endometrial Angiopoietin Expression and Modulation by Thrombin and Steroid Hormones: A Mechanism for Abnormal Angiogenesis Following Long-Term Progestin-Only Contraception Am. J. Pathol., June 1, 2004; 164(6): 2101 - 2107. [Abstract] [Full Text] [PDF]

				T. Saisto, A. Tiitinen, V.-M. Ulander, and R. Kaaja Clinical cure of severe, early onset preeclampsia with low molecular weight heparin therapy in primigravida with hyperreactio luteinalis and thrombophilia Hum. Reprod., March 1, 2004; 19(3): 725 - 728. [Abstract] [Full Text] [PDF]

				S Mehraein, H Ortwein, M Busch, M Weih, K Einhaupl, and F Masuhr Risk of recurrence of cerebral venous and sinus thrombosis during subsequent pregnancy and puerperium J. Neurol. Neurosurg. Psychiatry, June 1, 2003; 74(6): 814 - 816. [Abstract] [Full Text] [PDF]

				H. G. Weed, M. A. Medow, A. E. Guttmacher, and F. S. Collins Genomic Medicine N. Engl. J. Med., February 20, 2003; 348(8): 759 - 760. [Full Text] [PDF]